

Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin)

Recombinant Antibody
Catalog # APR10424

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	O95436
Reactivity	Human
Clonality	ADC
Isotype	IgG1
Calculated MW	75759

Additional Information


Target/Specificity	NaPi2b / SLC34A2
Endotoxin Conjugation	MMAE
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Protein Information


Name	SLC34A2
Function	Involved in actively transporting phosphate into cells via Na(+) cotransport.
Cellular Location	Apical cell membrane {ECO:0000250 UniProtKB:Q9DBP0}; Multi-pass membrane protein. Note=Localized at the brush border membranes of enterocytes. {ECO:0000250 UniProtKB:Q9DBP0}
Tissue Location	Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.

Images


Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) on SDS-PAGE under reducing (R) condition. The




purity of the protein is greater than 95%.




The purity of Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is more than 95%, determined by SEC-HPLC.




The drug-to-antibody ratio (DAR) of the Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is 3.7.



Human NaPi2b CHO-S Cells were stained with Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS



Human NaPi2b HEK293 Cell Line were stained with Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.9793 ug/mL.



Immobilized Human NaPi2b / SLC34A2, VLP at 5 µg/mL can bind Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) , EC50=0.06175 ug/mL.